Chondrosarcoma, an uncommon and lethal bone cancer that begins in the cells of cartilage has recently seen notable changes in market trends. This global market of Chondrosarcoma is witnessing a great acceleration of research and development focused on finding better therapies as well as increased focus on early detection and diagnosis. Such developments are majorly attributed to increased awareness about the disease, improved medical technology and increased number of cases of Chondrosarcoma worldwide.
One current trend in the Chondrosarcoma market is the emerging emphasis on novel therapeutic approaches. Traditional methods such as surgery as well as chemotherapy are crucial, nonetheless there has been an increasing demand for targeted drugs and immunotherapies. In order to achieve this direction towards personalized medicine, scientists have started investigating molecular pathways and genetic factors associated with Chondrosarcoma so that they can develop precision drugs that target specific mechanisms driving their growth. Consequently, positive outcomes would be achieved while minimizing side effects.
Another key thing to note about market trends for chondrosarcomas regards more attention being given to early detection and accurate diagnosis. As with most cancers, early intervention plays a significant role in prognosis & treatment outcomes for Chondrosarcoma patients. Improved imaging techniques for instance MRI and CT scans have made it much easier to identify tumors precisely located within the body. Moreover, biomarkers development alongside genetic testing techniques allows earlier diagnosis of this type of cancer thus facilitating timely intervention.
There has been a momentum attributed to collaborative efforts between pharmaceutical companies, research institutions and regulatory bodies in relation to Chondrosarcoma research. Clinical trials are being carried out globally to evaluate safety plus efficacy of new therapeutic options therefore providing hope for those patients who have limited access to treatment alternatives. Regulatory framework is evolving so as to hasten approval process for innovative treatments targeting this rare yet highly aggressive form of cancer.
Moreover, they show rising socio-economic impact consciousness of Chondrosarcoma. Advocacy groups and non-profit organizations are actively involved in raising awareness about the disease, providing support and funding research initiatives. Through this strategy, a more comprehensive knowledge regarding the condition as well as its impacts on patients’ lives is being obtained thereby leading to holistic improvements in Chondrosarcoma care.”
The Global Chondrosarcoma Market is projected to reach USD 1,321.4 Million by 2030 at 6.8% CAGR during the forecast period 2022-2030.
Chondrosarcoma is a rare type of bone cancer that consist predominantly of cartilage. It mostly affect pelvis, upper arms (humerus), thighs (femur), ribs, and shoulder blades (scapula) and is the most common in people older than 40 years.
Rising funding for R&D and clinical trials as well as FDA approvals are major driving forces for global chondrosarcoma market. Major players are funding large amount of money in new product development for effective cure that is another key driver for the market.
In August 2022, the European Commission (EC) gave orphan medicinal product designation to Inhibrx, Inc. for INBRX-109 in chondrosarcoma following a positive opinion from the European Medicines Agency (EMA). The EC grants orphan designation to drugs and biologics intended for the safe and effective treatment, prevention, or diagnosis of a disease that is life-threatening or chronically debilitating, impacting fewer than five in 10,000 patients in the European Union. Orphan drug designation in the EU can provide certain benefits, such as reduced regulatory fees, clinical protocol assistance, and up to ten years of market exclusivity upon regulatory approval. Chondrosarcoma is an orphan bone cancer that accounts for roughly 2,800 new cases each year in the U.S. and EU together. For this condition, there are no approved therapies.
In May 2023, Servier will be showcasing new data across its robust global oncology portfolio at ASCO – June 2-6th designed to bring tomorrow closer to our patients with cancer from all around the globe–. These latest data, including plenary session selection indicating Servier’s expansive oncology pipeline &portfolio as well as the company’s commitment to improving outcomes for underserved high unmet medical needs cancer types in hard-to-treat settings, have been submitted for consideration by ASCO abstract reviewers fare indicative of what we want these conditions in order get a better response from them. A breaking abstract with results from the Phase III INDIGO study of vorasidenib among patients with residual or recurrent grade II IDH-mutant glioma will also be presented at ASCO.
Study objectives of Global Chondrosarcoma Market:
FIGURE 1 GLOBAL CHONDROSARCOMA MARKET SHARE BY TYPES, 2016 (%)
Intended Audience:
Research Methodology:
Sources: National Center for Biotechnology Information, National Kidney Foundation, Inc., CheckOrphan, Directorate of Industries, Annual report, White paper, Company Presentation
Global Chondrosarcoma Market Segmentation
Global chondrosarcoma market has been segmented on the basis of types which comprises of conventional chondrosarcoma, clear cell chondrosarcoma, myxoid chondrosarcoma, mesenchymal chondrosarcoma, de-differentiated chondrosarcoma.
On the basis of diagnosis, it is segmented into biopsy, imaging, and others. Biopsy is further sub-segmented into shave open biopsy, core needle biopsy, and others. Imaging is further sub-segmented into X-Ray, Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scan, and others.
On the basis of treatment, the market has been segmented into intensive surgery, therapies, hemipelvectomy, and others. Therapies are further sub-segmented into physical therapy, radiation therapy, chemotherapy, and others. Hemipelvectomy is further sub-segmented into external hemipelvectomy, internal hemipelvectomy, and others.
On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.
Considering the global scenario of the market, North America holds the largest market share owing to various factors such as increasing prevalence of chondrosarcoma and increasing investment in R&D. Europe is the second largest market due to advanced healthcare facilities where the countries like Germany and UK are holding the largest market share. New cases of chondrosarcoma are rising in Asia Pacific region. Additionally, improving healthcare infrastructure and rising healthcare expenditure are driving the growth for Asia Pacific chondrosarcoma market. Due to low knowledge of disease and treatment, Middle East and Africa (ME&A) is likely to have a limited growth in the market.
Some of the key players in this market are:
The report for Global Chondrosarcoma Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)